title: Toll-like receptors 7 and 8 expression is associated with poor outcome and greater inflammatory response in acute ischemic stroke.
abstract: Toll-like receptors are innate immunity receptors that activate inflammation and adaptive immunity. Our objectives were to analyze the association between TLR3, 7, 8 and 9 expressions and clinical outcome in patients with ischemic stroke and the expression of inflammatory molecules. One hundred-ten patients with ischemic stroke were included within 12h of symptoms onset. Stroke severity was evaluated by the NIHSS, and functional outcome was assessed at 3 months by the modified Rankin Scale. Infarct volume at 4-7 days was measured on Computed Tomography imaging. TLR7 and TLR8 at different time points were independently associated with poor outcome. TLR8 was also correlated with infarct volumes. Furthermore, TLR7 and TLR8 on admission were correlated with levels of IL6 and IL1β at 24h, 72 h and 7 days. In conclusion, TLR 7 and TLR8 expressions are associated with poor outcome and greater inflammatory response in acute ischemic stroke.
authors.affiliation: Clinical Neuroscience Research Laboratory, Department of Neurology, Hospital Clínico Universitario, University of Santiago de Compostela, Santiago de Compostela, Spain.
authors.forename: David
authors.initials: D
authors.lastname: Brea
authors.forename: Tomás
authors.initials: T
authors.lastname: Sobrino
authors.forename: Manuel
authors.initials: M
authors.lastname: Rodríguez-Yáñez
authors.forename: Pedro
authors.initials: P
authors.lastname: Ramos-Cabrer
authors.forename: Jesús
authors.initials: J
authors.lastname: Agulla
authors.forename: Raquel
authors.initials: R
authors.lastname: Rodríguez-González
authors.forename: Francisco
authors.initials: F
authors.lastname: Campos
authors.forename: Miguel
authors.initials: M
authors.lastname: Blanco
authors.forename: José
authors.initials: J
authors.lastname: Castillo
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001281:Atrial Fibrillation / Q000503:physiopathology; D001786:Blood Glucose / Q000378:metabolism; D020520:Brain Infarction / Q000209:etiology / Q000473:pathology; D002545:Brain Ischemia / Q000150:complications*; D002097:C-Reactive Protein / Q000378:metabolism; D015815:Cell Adhesion Molecules / Q000097:blood; D005260:Female; D015870:Gene Expression / Q000235:genetics / Q000276:immunology; D006801:Humans; D007249:Inflammation / Q000097:blood; D053583:Interleukin-1beta / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D007963:Leukocytes, Mononuclear / Q000378:metabolism; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000097:blood; D008875:Middle Aged; D011379:Prognosis; D020521:Stroke / Q000175:diagnosis* / Q000209:etiology / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D051196:Toll-Like Receptor 3 / Q000235:genetics / Q000378:metabolism; D051199:Toll-Like Receptor 7 / Q000235:genetics / Q000378:metabolism*; D051200:Toll-Like Receptor 8 / Q000235:genetics / Q000378:metabolism*; D051217:Toll-Like Receptor 9 / Q000235:genetics / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D001786:Blood Glucose; D015815:Cell Adhesion Molecules; C508600:IL6 protein, human; D053583:Interleukin-1beta; D015850:Interleukin-6; C495344:TLR3 protein, human; C495348:TLR7 protein, human; C495349:TLR8 protein, human; C495371:TLR9 protein, human; D051196:Toll-Like Receptor 3; D051199:Toll-Like Receptor 7; D051200:Toll-Like Receptor 8; D051217:Toll-Like Receptor 9; D014409:Tumor Necrosis Factor-alpha; D002097:C-Reactive Protein; D020780:Matrix Metalloproteinase 9